MY103182A - Vaccines against acquired immune deficiency syndrome. - Google Patents

Vaccines against acquired immune deficiency syndrome.

Info

Publication number
MY103182A
MY103182A MYPI87002188A MYPI19872188A MY103182A MY 103182 A MY103182 A MY 103182A MY PI87002188 A MYPI87002188 A MY PI87002188A MY PI19872188 A MYPI19872188 A MY PI19872188A MY 103182 A MY103182 A MY 103182A
Authority
MY
Malaysia
Prior art keywords
immune deficiency
acquired immune
deficiency syndrome
lav
vaccines
Prior art date
Application number
MYPI87002188A
Inventor
Hu Shiu-Lok
Madisen Linda
F Purchio Anthony
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of MY103182A publication Critical patent/MY103182A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

RECOMBINANT VIRUSES WHICH DIRECT THE EXPRESSION OF PEPTIDES OR PROTEINS RELATED TO EPITOPES OF LAV/HTLV III, THE ETIOLOGICAL AGENT OF LYMPHADENOPATHY SYNDROME AND ACQUIRED IMMUNE DEFICIENCY SYNDROME, ARE DESCRIBED. THESE VIRUSES CAN BE FORMULATED AS VIRAL VACCINES OR IN MULTIVALENT VACCINES THAT PROTECT AGAINST LAV/HTLV III INFECTION. ANTIGENIC PEPTIDES AND PROTEINS RELATED TO EPITOPES OF LAV/HTLV III ARE ALSO DESCRIBED. THESE CAN BE PREPARED USING RECOMBINANT DNA TECHNIQUES OR BY CHEMICAL SYNTHESIS AND CAN BE USED AS IMMUNOGENS IN SUBNIT VACCINES OR AS ANTIGENS IN DIAGNOSTIC IMMUNOASSAYS.
MYPI87002188A 1985-09-25 1987-09-29 Vaccines against acquired immune deficiency syndrome. MY103182A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (1)

Publication Number Publication Date
MY103182A true MY103182A (en) 1993-05-29

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI87002188A MY103182A (en) 1985-09-25 1987-09-29 Vaccines against acquired immune deficiency syndrome.

Country Status (22)

Country Link
CN (1) CN1020752C (en)
AT (1) ATA256786A (en)
CH (1) CH676247A5 (en)
DE (1) DE3690508T1 (en)
DK (1) DK455486A (en)
ES (2) ES2002490A6 (en)
FI (1) FI863848L (en)
FR (1) FR2587720A2 (en)
GB (1) GB2181435B (en)
GR (1) GR862412B (en)
HU (1) HU205780B (en)
IE (1) IE59314B1 (en)
IL (1) IL80073A (en)
IT (1) IT1195829B (en)
MY (1) MY103182A (en)
NL (1) NL8602422A (en)
NO (1) NO863803L (en)
NZ (1) NZ217645A (en)
PT (1) PT83434B (en)
SE (4) SE8604007L (en)
WO (1) WO1987002038A1 (en)
YU (1) YU46753B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006099A1 (en) * 1985-04-08 1986-10-23 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
ATE107861T1 (en) * 1986-09-19 1994-07-15 Oncogen USE OF ACTIVATED T-LYMPHOCYTES TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AIDS.
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
JPS63258575A (en) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション Recombinant hiv envelope protein produced in insect cell
FR2610632B1 (en) * 1987-02-11 1990-12-21 Pasteur Institut CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
ES2104556T3 (en) * 1987-01-16 1997-10-16 Pasteur Institut PEPTIDES THAT HAVE IMMUNOLOGICAL PROPERTIES OF HIV-2.
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
FR2620030B1 (en) * 1987-09-07 1990-03-23 Transgene Sa VECTOR FOR THE EXPRESSION OF PROTEINS OF HIV-2 VIRUS, A CAUSAL AGENT FOR AIDS, CELL CULTURE INFECTED OR TRANSFORMED THROUGH THIS VECTOR, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
ES2059823T3 (en) * 1988-05-06 1994-11-16 Ferropas Ag METHODS AND SYSTEMS FOR PRODUCING HIV ANTIGENS.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE69031735T2 (en) * 1989-04-18 1998-03-12 Applied Biotechnology Inc GENERATION OF HYBRID GENES AND PROTEINS BY RECOMBINATION BY VIRUS
EP1288304A3 (en) * 1989-06-01 2006-04-05 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
FR2676068B1 (en) * 1991-05-02 1994-11-04 Pasteur Institut IMMUNOGENIC RECOMBINANT STRAINS OF B. ANTHRACIS - IMMUNOGENIC COMPOSITIONS CONTAINING THEM.
AU672372B2 (en) * 1991-11-08 1996-10-03 Pharmacia & Upjohn Company Feline leukemia virus vaccines
ATE220327T1 (en) 1992-09-29 2002-07-15 Inhale Therapeutic Syst PULMONARY RELEASE OF ACTIVE FRAGMENTS OF THE PARATHORMONE
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
ES2218543T3 (en) 1994-03-07 2004-11-16 Nektar Therapeutics PROCEDURE AND PREPARATION FOR THE ADMINISTRATION OF INSULIN BY PULMONARY ROUTE.
JPH11511112A (en) 1995-02-10 1999-09-28 ユニバーシティ・オブ・マサチューセッツ Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
DE59507617D1 (en) * 1995-09-06 2000-02-17 Schablonentechnik Kufstein Ag Process for making a screen printing stencil
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78293T1 (en) * 1983-05-27 1992-08-15 Texas A & M Univ Sys METHOD OF GENERATING A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
WO1986002383A1 (en) * 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
FI861626A7 (en) * 1985-04-19 1986-10-20 Hoffmann La Roche FOERVAERVAT IMMUNBRIST SYNDROME (AIDS) -RELATERAT VIRALT RECOMBINANT HOELJEPROTEIN SAMT ETT TESTFOERFARANDE FOER AIDS.
FR2586427B1 (en) * 1985-08-20 1988-12-09 Pasteur Institut NUCLEOTIDE AND POLYPEPTIDE SEQUENCES FROM VISNA VIRUS AND THEIR APPLICATION TO DIAGNOSTIC TESTS AND THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS

Also Published As

Publication number Publication date
GB2181435A (en) 1987-04-23
FI863848A7 (en) 1987-03-26
IL80073A (en) 1995-01-24
CH676247A5 (en) 1990-12-28
GB8622987D0 (en) 1986-10-29
GB2181435B (en) 1990-01-10
WO1987002038A1 (en) 1987-04-09
FR2587720B2 (en) 1995-02-10
DK455486A (en) 1987-03-26
IT1195829B (en) 1988-10-27
PT83434B (en) 1988-07-29
IT8667730A0 (en) 1986-09-24
FI863848L (en) 1987-03-26
FR2587720A2 (en) 1987-03-27
SE8604007L (en) 1987-03-26
FI863848A0 (en) 1986-09-24
NL8602422A (en) 1987-04-16
SE9102974D0 (en) 1991-10-14
SE9102976L (en) 1993-04-15
SE9102976D0 (en) 1991-10-14
IL80073A0 (en) 1986-12-31
ES2002490A6 (en) 1988-08-16
ATA256786A (en) 1995-05-15
DE3690508T1 (en) 1988-06-23
ES2006941A6 (en) 1989-05-16
SE9102974L (en) 1993-04-15
HUT42133A (en) 1987-06-29
NO863803D0 (en) 1986-09-24
CN1020752C (en) 1993-05-19
PT83434A (en) 1986-10-01
DK455486D0 (en) 1986-09-24
CN86106632A (en) 1987-05-13
NO863803L (en) 1987-03-26
HU205780B (en) 1992-06-29
YU165486A (en) 1989-08-31
GR862412B (en) 1987-01-23
SE9102975L (en) 1993-04-15
NZ217645A (en) 1991-11-26
IE862525L (en) 1987-03-25
SE9102975D0 (en) 1991-10-14
YU46753B (en) 1994-05-10
SE8604007D0 (en) 1986-09-23
IE59314B1 (en) 1994-02-09

Similar Documents

Publication Publication Date Title
SE9102974L (en) ADENOVIRA AND VALUES FOR USE FOR THE MANUFACTURE OF HIV PROTEINS AND PEPTIDES
ES8801318A1 (en) Gag antigen and its use for the detection of lav infection and in immunogenic compositions
ATE258188T1 (en) RETRO, INVERSO, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGS
SE8701413D0 (en) EXPRESSION AND PURIFICATION OF AN HTLV-III GAG / ENV GENE PROTEIN
DK0584348T3 (en) Genetic vaccine against immunodeficiency viruses
ATE109795T1 (en) HTLV-III ENCODING PEPTIDES.
FI941199A0 (en) Immunoreactive hepatitis C virus polypeptide compositions
DK513388A (en) PEPTIDES WITH IMMUNOLOGICAL PROPERTIES RESPONSIBLE FOR HIV-2 VIRUSES, NUCLEOTIDE SEQUENCES CODING FOR SUCH PEPTIDES, ANTIGEN AND IMMUNOGENIC AGENTS CONTAINING SUCH PEPTIDES AND PROCEDURES AND HIV KIT TILT INIT
WO1991004273A3 (en) Novel peptides associated with the cd4 binding region of gp120 and their methods of use
DK614987A (en) SYNTHETIC HTLV-III PEPTIDES, PREPARATIONS AND APPLICATIONS THEREOF
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
ATE105334T1 (en) CHIMAERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SECTIONS OF HUMAN PARAINFLUENZAVIRUS TYPE 3.
FI823021A7 (en) Products that demonstrate the antigenicity of hepatitis B virus e antigen and methods for preparing these antigens.
NO912825D0 (en) PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IMMUNOGENIC PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS.
DK169986D0 (en) THE ANTIGEN RELATED TO THE GLYCOPROTEIN IN AIDS VIRUS, ISA PRESIDENT FOR THE GLYCOPROTEIN AND PROCEDURE FOR THE PREPARATION OF SUCH ANTIGEN
ATE188484T1 (en) IMMUNOLOGICALLY HLA HOMOLOGUE HIV PROTEIN EPITOPES
ATE72400T1 (en) CROSS-REACTIVE AND PROTECTIVE EPITOPES OF CIRCUMSPOROZOITE PROTEINS.
ZA873922B (en) Method of preparation and use for feline leukemia virus antigens
DE69433057D1 (en) PEPTIDES FOR USE IN VACCINATING AND INDUCING NEUTRALIZING ANTIBODIES AGAINST THE HUMAN IMMUNE VIRUS
SE8700466D0 (en) VACCINES AGAINST MELANOMA
ATE122236T1 (en) PRECURSOR OF THE ENVELOPE GLYCOPROTEIN OF THE HIV-2 RETROVIRUS AND RELATED ANTIGENS.
SU1739559A1 (en) TREATMENT OF APHTAE EPIZOOTICAE VIRUS TYPE O, USED TO MAKE DIAGNOSTIC SERIES AND ANTIGEN DRUGS